Predictive value of captopril transit renography in essential hypertension and diabetic nephropathy.
Predictive value of captopril transit renography in essential hypertension and diabetic nephropathy.
复制标题
卡托普利转运肾图对原发性高血压和糖尿病肾病的预测价值。
DOI：
10.1097/00006231-199501000-00004
复制
发表时间：
1995
影响因子：
1.5
通讯作者：
K. Britton
中科院分区：
文献类型：
--
作者：
I. Datseris;K. Sonmezoglu;Q. Siraj;J. Bomanji;C. Nimmon;K. Nijran;K. Britton
卡托普利肾图用于评估 (1) 28 名肾功能未受损的轻至中度原发性高血压 (EH) 患者和 (2) 25 名患有糖尿病肾病 (HDN) 的高血压患者是否存在血管紧张素 II 依赖性肾血管功能障碍。这些研究根据卡托普利肾图肾血管性高血压诊断标准工作组概述的诊断标准进行分类，并使用平均实质传输时间（MPTT）作为检测是否存在血管紧张素II依赖性肾血流动力学变化的指标。 EH 患者的 MPTT 表现出不显着或非特异性的改变。 HDN 组中的 4 名患者在因肾动脉狭窄导致肾素-血管紧张素-醛固酮激活的情况下表现出 MPTT 显着延长，而该组中的其他患者在卡托普利后表现出 MPTT 显着降低，这与仅存在微血管病变的情况下血流量增加和肾小管转运功能改善一致。我们的结论是，将 MPTT 添加到卡托普利肾图检查的标准诊断标准中可能有助于预测 HDN 中血管紧张素 II 抑制治疗的有益或有害影响，并将 EH 中的测试方案限制为一项卡托普利后研究。
Captopril renography was utilized to assess the presence of angiotensin II dependent renovascular dysfunction in (1) 28 patients with mild to moderate essential hypertension (EH) with unimpaired renal function, and (2) 25 hypertensive patients with diabetic nephropathy (HDN). These studies were classified according to the diagnostic criteria outlined by the Working Party on Diagnostic Criteria of Renovascular Hypertension with Captopril Renography and the mean parenchymal transit time (MPTT) was used as an index for detecting the presence of angiotensin II dependent renal haemodynamic change. Patients with EH showed non-significant or non-specific alterations in the MPTT. Four patients in the HDN group showed a significant prolongation of MPTT in the presence of renin-angiotensin-aldosterone activation due to renal artery stenosis, and the other patients in this group showed a significant decrease in MPTT after captopril, consistent with increased blood flow and improved tubular transport function in the presence of microangiopathy only. We conclude that addition of MPTT to the standard diagnostic criteria of captopril renography may be helpful in predicting the beneficial or detrimental impact of angiotensin II inhibition treatment in HDN and in limiting the test protocol in EH to one post-captopril study.